Dabrafenib (GSK2118436A) is an ATP-competitive Raf inhibitor with IC50 values of 5 nM (C-Raf) and 0.6 nM (B-Raf^V600E). It inhibits NRAS mutant cell growth when combined with GSK1120212 and reduces S6P phosphorylation in A375 cells. Dabrafenib also suppresses PolyP-mediated vascular permeability, inflammation, leukocyte adhesion, and NF-κB, TNF-α, and IL-6 activation. Additionally, it inhibits HMGB1 release and downregulates HMGB1-driven inflammatory responses by enhancing CAM expression in endothelial cells. Reagent grade, for research use only.
Usually ships within 24 hours.